271. Ankylosing spondylitis Clinical trials / Disease details


Clinical trials : 563 Drugs : 372 - (DrugBank : 72) / Drug target genes : 41 - Drug target pathways : 145

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03473665
(ClinicalTrials.gov)
March 1, 201813/3/2018Non-Steroidal Anti-inflammatory Drugs in Axial SpondyloarthritisNon-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot StudyAnkylosing Spondylitis;Axial SpondyloarthritisDrug: Indomethacin;Drug: Diclofenac;Drug: Meloxicam;Drug: CelecoxibColumbia UniversityNULLTerminated18 YearsN/AAll9Phase 4United States
2ChiCTR-TRC-11001417
2011-06-012011-07-10clinical study of Mecenchymal Stem Cells transplantation in Ankylosing Spondylitisclinical study of Mecenchymal Stem Cells transplantation in Ankylosing Spondylitis Ankylosing Spondylitis (AS)1:oral salicylazosulfapyridine and indomethacin;2:Mecenchymal Stem Cells(MSC) transplantation ;Sun Yat-sen Memorial Hospital of Sun Yat-sen UniversityNULLRecruitingBoth1:80;2:80;I+2 (Phase 1+Phase 2)China
3NCT02183168
(ClinicalTrials.gov)
July 20014/7/2014Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing SpondylitisA Randomized, Open Label, 3-arm Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing SpondylitisSpondylitis, AnkylosingDrug: Meloxicam suppository;Drug: Meloxicam tablet;Drug: IndomethacinBoehringer IngelheimNULLCompletedN/AN/ABoth192Phase 3NULL